Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells

Bioconjugate Chemistry

Volumn 23, Issue 8, 2012, Pages 1507-1512

  Dreaden, Erik C ^a,c   Gryder, Berkley E ^a   Austin, Lauren A ^a   Tene Defo, Brice A ^a   Hayden, Steven C ^a   Pi, Min ^b   Quarles, L Darryl ^b   Oyelere, Adegboyega K ^a   El Sayed, Mostafa A ^a  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; CHEMOTHERAPY; DIAGNOSIS; DRUG DELIVERY; FIBER OPTIC SENSORS; GOLD NANOPARTICLES; METAL NANOPARTICLES; UROLOGY;

ANDROGEN RECEPTORS; CANCER SCREENING; CELL-BE; CELL/B.E; CELL/BE; CLINICAL THERAPY; DEVELOPED COUNTRIES; MALIGNANT CELLS; PROSTATE CANCER CELLS; PROSTATE CANCERS;

DISEASES;

ALPHA BICALUTAMIDE LIGAND; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BETA BICALUTAMIDE LIGAND; BICALUTAMIDE; G PROTEIN COUPLED RECEPTOR; GOLD NANOPARTICLE; GPRC6A PROTEIN; UNCLASSIFIED DRUG;

ANTIANDROGEN THERAPY; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; ZETA POTENTIAL;

EID: 84865116618     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300158k     Document Type: Article

References (38)

1. Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., and Parkin, D. M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int. J. Cancer 127, 2893-2917
2. Siegel, R., Ward, E., Brawley, O., and Jemal, A. (2011) Cancer statistics CA Cancer J. Clin. 61, 212-236
3. Statistics on the risk of developing cancer, Cancer Research UK, accessed 7 December, 2011, http://info.cancerresearchuk.org/cancerstats/incidence/risk/.
4. Chen, Y., Clegg, N. J., and Scher, H. I. (2009) Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 10, 981-991
5. Attar, R. M., Takimoto, C. H., and Gottardis, M. M. (2009) Castration-resistant prostate cancer: locking up the molecular escape routes Clin. Cancer Res. 15, 3251-3255
6. Borsellino, N., Belldegrun, A., and Bonavida, B. (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines Cancer Res. 55, 4633-4639
7. Dreaden, E. C., Mwakwari, S. C., Sodji, Q. H., Oyelere, A. K., and El-Sayed, M. A. (2009) Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment Bioconjugate Chem. 20, 2247-2253
8. Dreaden, E. C., Alkilany, A. M., Huang, X., Murphy, C. J., and El-Sayed, M. A. (2012) The golden age: gold nanoparticles for biomedicine Chem. Soc. Rev. 41, 2740-2779
9. Dhar, S., Gu, F. X., Langer, R., Farokhzad, O. C., and Lippard, S. J. (2008) Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles Proc. Natl. Acad. Sci. U.S.A. 105, 17356-17361
10. Dhar, S., Kolishetti, N., Lippard, S. J., and Farokhzad, O. C. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 2011, not SUPPL.ied.
11. Hattori, Y. and Maitani, Y. (2005) Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase Cancer Gene Ther. 12, 796-809 (Pubitemid 43086281)
12. Xue, H.-Y. and Wong, H.-L. (2011) Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner ACS Nano 5, 7034-7047
13. Chanda, N., Kattumuri, V., Shukla, R., Zambre, A., Katti, K., Upendran, A., Kulkarni, R. R., Kan, P., Fent, G. M., Casteel, S. W., Smith, C. J., Boote, E., Robertson, J. D., Cutler, C., Lever, J. R., Katti, K. V., and Kannan, R. (2010) Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity Proc. Natl. Acad. Sci. U.S.A. 107, 8760-8765
14. Roa, W., Zhang, X., Guo, L., Shaw, A., Hu, X., Xiong, Y., Gulavita, S., Patel, S., Sun, X., Chen, J., Moore, R., and Xing, J. Z. (2009) Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle Nanotechnology 20, 375101
15. Stern, J. M., Stanfield, J., Kabbani, W., Hsieh, J.-T., and Cadeddu, J. A. (2008) Selective prostate cancer thermal ablation with laser activated gold nanoshells J. Urol. 179, 748-753
16. Pedram, A., Razandi, M., Sainson, R. C. A., Kim, J. K., Hughes, C. C., and Levin, E. R. (2007) A conserved mechanism for steroid receptor translocation to the plasma membrane J. Biol. Chem. 282, 22278-22288 (Pubitemid 47267344)
17. Hatzoglou, A., Kampa, M., Kogia, C., Charalampopoulos, I., Theodoropoulos, P. A., Anezinis, P., Dambaki, C., Papakonstanti, E. A., Stathopoulos, E. N., Stournaras, C., Gravanis, A., and Castanas, E. (2005) Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo J. Clin. Endocrinol. Metab. 90, 893-903 (Pubitemid 40279214)
18. Pi, M. and Quarles, L. D. (2011) GPRC6A regulates prostate cancer progression Prostate 72, 399-409
19. Dreaden, E. C., Mackey, M. A., Huang, X., Kang, B., and El-Sayed, M. A. (2011) Beating cancer in multiple ways using nanogold Chem. Soc. Rev. 40, 3391-3404
20. Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., and Dalton, J. T. (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U.S.A. 102, 6201-6206 (Pubitemid 40594278)
21. Jiang, W., Kim, B. Y. S., Rutka, J. T., and Chan, W. C. W. (2008) Nanoparticle-mediated cellular response is size-dependent Nat. Nanotechnol. 3, 145-150 (Pubitemid 351355131)
22. Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., and Chan, W. C. W. (2009) Mediating tumor targeting efficiency of nanoparticles through design Nano Lett. 9, 1909-1915
23. Obach, R. S., Lombardo, F., and Waters, N. J. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds Drug Metab. Dispos. 36, 1385-1405 (Pubitemid 351929323)
24. Zhou, J., Liu, B., Geng, G., and Wu, J. H. (2010) Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens Proteins 78, 623-637
25. He, Y., Yin, D., Perera, M., Kirkovsky, L., Stourman, N., Li, W., Dalton, J. T., and Miller, D. D. (2002) Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor Eur. J. Med. Chem. 37, 619-634 (Pubitemid 34874896)
26. Kirkovsky, L., Mukherjee, A., Yin, D., Dalton, J. T., and Miller, D. D. (2000) Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring1 J. Med. Chem. 43, 581-590 (Pubitemid 30127153)
27. Papadopoulou, N., Charalampopoulos, I., Anagnostopoulou, V., Konstantinidis, G., Foller, M., Gravanis, A., Alevizopoulos, K., Lang, F., and Stournaras, C. (2008) Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells. Mol. Cancer 7.
28. Gu, S., Papadopoulou, N., Gehring, E.-M., Nasir, O., Dimas, K., Bhavsar, S., Föller, M., Alevizopoulos, K., Lang, F., and Stournaras, C. (2009) Functional membrane androgen receptors in colon tumors trigger pro-apoptotic responses in vitro and reduce drastically tumor incidence in vivo Mol. Cancer 8, 1-14
29. Kampa, M., Kogia, C., Theodoropoulos, P. A., Anezinis, P., Charalampopoulos, I., Papakonstanti, E. A., Stathopoulos, E. N., Hatzoglou, A., Stournaras, C., Gravanis, A., and Castanas, E. (2006) Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells Mol. Cancer Ther. 5, 1342-1351 (Pubitemid 43881328)
30. Heinlein, C. A. and Chang, C. (2004) Androgen receptor in prostate cancer Endocr. Rev. 25, 276-308 (Pubitemid 38501396)
31. Schuh-Huerta, S. M. and Pera, R. A. R. (2011) Reproductive biology: Bone returns the favour Nature 472, 46-47
32. Wellendorph, P. and Bräuner-Osborne, H. (2004) Molecular cloning, expression, and sequence analysis of GPRC6A, a novel family C G-protein-coupled receptor Gene 335, 37-46 (Pubitemid 38759751)
33. Takata, R., Akamatsu, S., Kubo, M., Takahashi, A., Hosono, N., Kawaguchi, T., Tsunoda, T., Inazawa, J., Kamatani, N., Ogawa, O., Fujioka, T., Nakamura, Y., and Nakagawa, H. (2010) Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population Nat. Genet. 42, 751-754
34. Pi, M., Parrill, A. L., and Quarles, L. D. (2010) GPRC6A mediates the non-genomic effects of steroids J. Biol. Chem. 285, 39953-39964
35. Whitaker, H. C., Hanrahan, S., Totty, N., Gamble, S. C., Waxman, J., Cato, A. C. B., Hurst, H. C., and Bevan, C. L. (2004) Androgen receptor is targeted to distinct subcellular compartments in response to different therapeutic antiandrogens Clin. Cancer Res. 10, 7392-7401 (Pubitemid 39489890)
36. Virolainen, E., Vanharanta, R., and Carey, T. E. (1984) Steroid hormone receptors in human squamous carcinoma cell lines Int. J. Cancer 33, 19-25 (Pubitemid 14223228)
37. Alimirah, F., Chen, J., Basrawala, Z., Xin, H., and Choubey, D. (2006) DU-145 and PC-3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation FEBS Lett. 580, 2294-2300 (Pubitemid 43675636)
38. Kreis, W., Budman, D. R., and Calabro, A. (2001) A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents Cancer Chemother. Pharmacol. 47, 78-82 (Pubitemid 32664517)